PMID- 34622787
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20231107
IS  - 2149-2271 (Electronic)
IS  - 2149-2263 (Print)
IS  - 2149-2263 (Linking)
VI  - 25
IP  - 10
DP  - 2021 Oct
TI  - Clinical efficacy, safety, tolerability, and survival outcome of long-term 
      inhaled iloprost treatment in the management of pulmonary arterial hypertension: 
      Data from prospective multicenter observational OPTION study.
PG  - 721-732
LID - 10.5152/AnatolJCardiol.2021.03009 [doi]
AB  - OBJECTIVE: To evaluate clinical efficacy, safety and tolerability of long-term 
      inhaled iloprost treatment in the daily practice for the management of pulmonary 
      arterial hypertension (PAH). METHODS: A total of 115 patients with PAH on inhaled 
      iloprost treatment were included. New York Heart Association (NYHA) functional 
      class, brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic 
      peptide (NT-proBNP) levels, and 6-minute walk distance (6MWD) were recorded at 
      baseline and at 3rd to 24th month visits. Safety and tolerability of iloprost 
      treatment were also evaluated during follow-up, as were the survival, clinical 
      worsening, and the related risk factors. RESULTS: The treatment was associated 
      with an increase in the percentage NYHA functional class II (from 0.0% at 
      enrolment to 36.2% at 24th month visit) patients but no significant difference 
      was noted in 6MWD values. Clinical worsening was observed in 63.5% patients, 
      while survival rate was 69.6%. NT-proBNP levels were significantly higher in 
      non-survivors than in survivors (p=0.042). Cox regression analysis revealed the 
      association of female sex [odds ratio (OR)=0.318; 95% confidence interval (CI), 
      0.128-0.792; p=0.014] and scleroderma-related PAH (OR=0.347; 95% CI, 0.140-0.860; 
      p=0.022) with significantly lower risk (3.14 fold and 2.88 fold, respectively) of 
      mortality. CONCLUSION: Our findings indicate favorable efficacy, safety, and 
      tolerability of long-term iloprost treatment in the management of PAH, whereas 
      improved NYHA functional class was not accompanied with a significant change in 
      6MWD values. Patient age was a risk factor for clinical worsening, while female 
      sex, scleroderma subtype, and lower NT-proBNP levels were associated with 
      significantly lower mortality risk.
FAU - Kucukoglu, Mehmet Serdar
AU  - Kucukoglu MS
AD  - Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, 
      Turkey.
FAU - Hanta, Ismail
AU  - Hanta I
AD  - Department of Chest Diseases, Cukurova University Faculty of Medicine, Adana, 
      Turkey.
FAU - Akdeniz, Bahri
AU  - Akdeniz B
AD  - Department of Cardiology, Dokuz Eylul University Faculty of Medicine, Izmir, 
      Turkey.
FAU - Gullulu, Sumeyye
AU  - Gullulu S
AD  - Department of Cardiology, Uludag University Faculty of Medicine, Bursa, Turkey.
FAU - Atahan, Ersan
AU  - Atahan E
AD  - Department of Chest Diseases, Istanbul University Cerrahpasa Faculty of Medicine, 
      Istanbul, Turkey.
FAU - Sayin, Tamer
AU  - Sayin T
AD  - Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey.
FAU - Okumus, Gulfer
AU  - Okumus G
AD  - Department of Chest Diseases, Istanbul University Istanbul Faculty of Medicine, 
      Istanbul, Turkey.
FAU - Onen, Zeynep Pinar
AU  - Onen ZP
AD  - Department of Chest Diseases, Ankara University Faculty of Medicine, Ankara, 
      Turkey.
FAU - Yokusoglu, Mehmet
AU  - Yokusoglu M
AD  - Department of Cardiology, Gulhane Military Medical Academy, Ankara, Turkey.
FAU - Baygul, Arzu
AU  - Baygul A
AD  - Department of Biostatistics, Koc University School of Medicine, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Turkey
TA  - Anatol J Cardiol
JT  - Anatolian journal of cardiology
JID - 101652981
RN  - JED5K35YGL (Iloprost)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Hypertension, Pulmonary/drug therapy
MH  - Iloprost/therapeutic use
MH  - Prospective Studies
MH  - *Pulmonary Arterial Hypertension
MH  - Treatment Outcome
PMC - PMC8504660
COIS- Conflict of interest: None declared.
EDAT- 2021/10/09 06:00
MHDA- 2021/10/21 06:00
PMCR- 2021/09/16
CRDT- 2021/10/08 08:43
PHST- 2021/10/08 08:43 [entrez]
PHST- 2021/10/09 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/09/16 00:00 [pmc-release]
AID - ajc-25-10-721 [pii]
AID - 10.5152/AnatolJCardiol.2021.03009 [doi]
PST - ppublish
SO  - Anatol J Cardiol. 2021 Oct;25(10):721-732. doi: 
      10.5152/AnatolJCardiol.2021.03009.